4-HO-MiPT

From PsychonautWiki
(Redirected from Miprocin)
Jump to: navigation, search
Summary sheet: 4-HO-MiPT
4-HO-MiPT
Molecular structure of 4-HO-MiPT.
4-HO-MiPT.svg
Chemical Nomenclature
Common names 4-HO-MiPT, Miprocin
Substitutive name 4-hydroxy-N-methyl-N-isopropyltryptamine
Systematic name 3-(2-[Isopropyl (methyl) amino]ethyl)-1H-indol-4-ol
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 5 - 10 mg
Light 10 - 15 mg
Common 15 - 25 mg
Strong 25 - 35 mg
Heavy 35 mg +
Duration
Total 4 - 6 hours
Onset 15 - 45 minutes
Come up 20 - 60 minutes
Peak 1.5 - 2.5 hours
Offset 1 - 2 hours
After effects 2 - 4 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

4-Hydroxy-N-methyl-N-isopropyltryptamine (also known as 4-HO-MiPT, and Miprocin) is a synthetic psychedelic substance of the tryptamine chemical class that produces effects similar to psilocin (the active component in psilocybin mushrooms) when administered. It is part of a series of psychedelic substituted tryptamines such as 4-AcO-DMT, 4-HO-MET, 4-HO-DiPT that are considered to produce variations of the core psychedelic effects typified by psilocin.

This substance is relatively uncommon and has only a short history of human use. Alexander Shulgin evaluated its activity in humans in 1979, describing a trial of 12mg as a richly insightful and highly erotic experience.[1] A description of 4-HO-MiPT is included in Shulgin's 1997 book TiHKAL.[2] Shulgin's trials and other anecdotal reports suggest that 4-HO-MiPT is similar in activity to psilocin, the active component in psilocybin mushrooms.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-HO-MiPT in humans. As with psilocin, there have been no reported deaths from 4-HO-MiPT use despite the existence of reports of people taking doses which far exceeds the active dose. This suggests that it is well-tolerated physiologically.[citation needed]

Today, 4-HO-MiPT is either used recreationally or as an entheogenic substance and is typically distributed as a grey-area research chemical by online vendors. After some time spent exclusively on the online market, there is evidence that suggests it is becoming increasingly popular on the streets, where prefilled capsules containing it have been found being sold as "shroom pills".[citation needed]

History and culture

History icon.svg

This History and Culture section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

The first synthesis of 4-HO-MiPT was published in 1981 by a team of chemists led by David Repke.[3] Repke and Shulgin later collaborated on a paper evaluating the effects of different oxygen substituents on the MiPT structure, describing 4-HO-MiPT as the most interesting of the series and the only one to possess classical hallucinogen effects.[4]

Chemistry

Generic structure of a tryptamine molecule.

4-HO-MiPT or 4-hydroxy-N-methyl-N-isopropyltryptamine is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 4-HO-MiPT is substituted at R4 of its indole heterocycle with a hydroxyl (HO) functional group OH-. It also contains a methyl group and an isopropyl chain bound to the terminal amine RN of its tryptamine backbone (MiPT). 4-HO-MiPT is the N-substituted isopropyl homologue of 4-HO-DMT (Psilocin).[5]

Pharmacology

Further information: Serotonergic psychedelic

4-HO-MiPT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

Multi-sensory effects
Gears.svg

Transpersonal effects
Infinity4.svg

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 4-HO-MiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 4-HO-MiPT is a research chemical with very little history of human usage. Anecdotal evidence from people within the community who have tried 4-HO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

4-HO-MiPT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 4-HO-MiPT are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 4-HO-MiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 4-HO-MiPT all psychedelics will have a reduced effect.

Legality

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Sweden: 4-HO-MiPT is classified as a health hazard under the act Lagen om förbud mot vissa hälsofarliga varor (translated as the "Act on the Prohibition of Certain Goods Dangerous to Health") as of November 1, 2005, making it illegal to sell or possess.[6]
  • United Kingdom: 4-HO-MiPT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.[7]
  • United States: 4-HO-MiPT is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT) which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.[citation needed]

See also

External links

Forums

References

  1. Shulgin, Alexander. "Pharmacology Lab Notes #2". Lafayette, CA. (1976-1980). p312 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook2_searchable.pdf
  2. http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=22 | 4-HO-MiPT (TiHKAL / Isomer Design)
  3. Repke, DB; Ferguson, WJ; Bates, DK. Psilocin analogs II. Synthesis of 3-[2-(dialkylamino)ethyl]-, 3-[2-(N-methyl-N-alkylamino)ethyl]-, and 3-[2-(cycloalkylamino)ethyl]indol-4-ols. J. Heterocycl. Chem., 1 Jan 1981, 18 (1), 175–179. 368 kB. http://dx.doi.org/10.1002/jhet.5570180131 | http://onlinelibrary.wiley.com/doi/10.1002/jhet.5570180131/abstract
  4. Repke, DB; Grotjahn, DB; Shulgin, AT. Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents. J. Med. Chem., 1 Jan 1985, 28 (7), 892–896. 711 kB. http://dx.doi.org/10.1021/jm00145a007 | http://pubs.acs.org/doi/abs/10.1021/jm00145a007
  5. http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=22
  6. http://www.notisum.se/rnp/sls/sfs/20050733.pdf
  7. Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e